Constant inflammatory cell infiltrationand pericyte-myofibroblast transition lead torenal fibrosis and insufficiency which result indecreased production of erythropoietin (4-7).Thus far, therapeutic efforts to treat patientswith chronic renal failure by administeringerythropoietin have been made only to correctanemia and putative hypoxic tissue damage.The introduction of recombinant human erythropoietinhas marked a significant advance inthe management of anemia associated withchronic renal failure (6-9). This evidence concerns the gene EPO and chronic kidney disease.